This article summarized the latest R&D progress of Norelgestromin, the Mechanism of Action for Norelgestromin, and the drug target R&D trends for Norelgestromin.
Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.
Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.
This article summarized the latest R&D progress of Oxiconazole Nitrate, the Mechanism of Action for Oxiconazole Nitrate, and the drug target R&D trends for Oxiconazole Nitrate.
Acetylcholinesterase (AChE), the primary cholinesterase in the body, is an enzyme catalyzing the breakdown of acetylcholine and of some other choline esters that function as neurotransmitters.
Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.
At the 38th Society for Immunotherapy of Cancer Meeting, Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126, revolutionizing new antibody-related therapies.
This article summarized the latest R&D progress of Paroxetine Mesylate, mechanism of action for Paroxetine Mesylate, and the drug target R&D trends for Paroxetine Mesylate.
ACE inhibitors are a class of drugs that work by relaxing blood vessels, inhibiting the production of the vasoconstrictor substance Angiotensin II. This results in lower blood pressure, reduced cardiac load, and decreased risk of hypertension.
A Contrast agent, also known as a contrast medium, is a specific substance that is introduced into the human body for the purpose of medical imaging – it is used to alter the contrast of images of parts of the body.